Response Oncology Cash And Equivalents vs. Revenue
Based on the key profitability measurements obtained from Response Oncology's financial statements, Response Oncology may not be well positioned to generate adequate gross income at the moment. It has a very high risk of underperforming in January. Profitability indicators assess Response Oncology's ability to earn profits and add value for shareholders.
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.
For Response Oncology profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Response Oncology to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Response Oncology utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Response Oncology's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Response Oncology over time as well as its relative position and ranking within its peers.
Response |
Response Oncology Revenue vs. Cash And Equivalents Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Response Oncology's current stock value. Our valuation model uses many indicators to compare Response Oncology value to that of its competitors to determine the firm's financial worth. Response Oncology is currently regarded as top stock in cash and equivalents category among its peers. It also is currently regarded number one company in revenue category among its peers totaling about 13.11 of Revenue per Cash And Equivalents. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Response Oncology's earnings, one of the primary drivers of an investment's value.Response Revenue vs. Cash And Equivalents
Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Response Oncology |
| = | 9.01 M |
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Response Oncology |
| = | 118.08 M |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Response Revenue vs Competition
Response Oncology is currently regarded number one company in revenue category among its peers. Market size based on revenue of Health Care industry is at this time estimated at about 27.21 Billion. Response Oncology adds roughly 118.08 Million in revenue claiming only tiny portion of equities under Health Care industry.
Response Oncology Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Response Oncology, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Response Oncology will eventually generate negative long term returns. The profitability progress is the general direction of Response Oncology's change in net profit over the period of time. It can combine multiple indicators of Response Oncology, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Response Oncology, Inc. does not have significant operations. Prior to the sale of its assets, it provided advanced cancer treatment services through outpatient facilities known as IMPACT Centers under the direction of practicing oncologists owned the assets of and managed the nonmedical aspects of oncology practices compounded and dispensed pharmaceuticals to certain oncologists for a fixed or cost plus fee and conducted outcomes research on behalf of pharmaceutical manufacturers. Response Oncology is traded on OTC Exchange in the United States.
Response Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Response Oncology. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Response Oncology position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Response Oncology's important profitability drivers and their relationship over time.
Use Response Oncology in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Response Oncology position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Response Oncology will appreciate offsetting losses from the drop in the long position's value.Response Oncology Pair Trading
Response Oncology Pair Trading Analysis
The ability to find closely correlated positions to Response Oncology could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Response Oncology when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Response Oncology - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Response Oncology to buy it.
The correlation of Response Oncology is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Response Oncology moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Response Oncology moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Response Oncology can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Response Oncology position
In addition to having Response Oncology in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Macroaxis Index Thematic Idea Now
Macroaxis Index
An experimental equal-weighted index theme of selected equities generated based on Macroaxis rating and scoring system. The Macroaxis Index theme has 52 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Macroaxis Index Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Other Consideration for investing in Response Stock
If you are still planning to invest in Response Oncology check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Response Oncology's history and understand the potential risks before investing.
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Fundamental Analysis View fundamental data based on most recent published financial statements |